Introduction {#section6-1352458514536252}
============

A large body of evidence indicates that infection with the Epstein--Barr virus (EBV) plays a major role in the pathogenesis of multiple sclerosis (MS), although its exact role is incompletely understood.^[@bibr1-1352458514536252],[@bibr2-1352458514536252]^ EBV is a ubiquitous human herpesvirus that has the unique ability to infect, activate and latently persist in B lymphocytes for the lifetime of the infected individual.^[@bibr3-1352458514536252]^ Normally EBV infection is kept under tight control by EBV-specific immune responses, especially by cytotoxic CD8^+^ T cells which eliminate proliferating and lytically infected B cells.^[@bibr4-1352458514536252]^ Since 1980 it has been recognized that MS patients have a decreased proportion and number of CD8^+^ T cells and increased CD4/CD8 T cell ratio in peripheral blood.^[@bibr5-1352458514536252][@bibr6-1352458514536252][@bibr7-1352458514536252][@bibr8-1352458514536252][@bibr9-1352458514536252][@bibr10-1352458514536252][@bibr11-1352458514536252][@bibr12-1352458514536252]--[@bibr13-1352458514536252]^ This was initially interpreted as a decrease in suppressor T cells leading to disinhibition of autoimmune responses^[@bibr5-1352458514536252],[@bibr6-1352458514536252]^ but later attributed to sequestration of CD8^+^ T cells in the central nervous system (CNS).^[@bibr11-1352458514536252]^ An alternative explanation is that the low number of circulating CD8^+^ T cells is genetically determined and results in a decreased CD8^+^ T cell response to EBV,^[@bibr2-1352458514536252]^ which in turn allows EBV-infected autoreactive B cells to accumulate in the CNS and lead to the development of MS.^[@bibr14-1352458514536252]^

Based on the expression of CD45RA, CCR7 and CD62L, human CD4^+^ T cells and CD8^+^ T cells can be subdivided into four major subsets with distinct homing and functional properties, namely: naïve (CD45RA^+^CCR7^+^CD62L^+^), central memory (CM) (CD45RA^--^CCR7^+^CD62L^+^), effector memory (EM) (CD45RA^--^CCR7^--^CD62L^--^) and effector memory re-expressing CD45RA (EMRA) (CD45RA^+^CCR7^--^CD62L^--^) cells.^[@bibr15-1352458514536252],[@bibr16-1352458514536252]^ Naïve and CM CD8^+^ T cells home to secondary lymphoid organs whereas EM and EMRA CD8^+^ T cells traffic to inflamed non-lymphoid tissues and exhibit effector functions such as interferon-γ production and cytotoxicity. Recent studies suggest it may be possible to subdivide memory T cells into additional types but this remains controversial.^[@bibr17-1352458514536252]^ In the current study we analyzed the memory phenotypes of CD4^+^ T cells and CD8^+^ T cells in MS patients and healthy subjects to determine which memory subsets are involved in the CD8^+^ T cell deficiency and how these subsets relate to clinical course.

Methods {#section7-1352458514536252}
=======

Patients and controls {#section8-1352458514536252}
---------------------

This study was approved by the Royal Brisbane and Women's Hospital Human Research Ethics Committee and The University of Queensland Medical Research Ethics Committee. Blood was collected from 118 MS patients and 112 age- and sex-matched healthy subjects following informed consent. The MS patient group included 14 patients with the first attack of the type seen in MS (clinically isolated syndrome (CIS)), 34 with relapsing--remitting MS (RRMS), 35 with secondary progressive MS (SPMS) and 35 with primary progressive MS (PPMS). Of the 48 patients with CIS or RRMS, 17 had had a clinical attack within 30 days of venesection, and 31 were in remission. All patients with RRMS, SPMS and PPMS met the 2005 and/or the 2010 Revised McDonald Criteria for a diagnosis of MS, and five of the CIS patients also met these criteria at later follow-up. The patients had not received corticosteroids or immunomodulatory therapy for at least three months prior to venesection. The demographic and clinical details of the healthy subjects and patients with MS are presented in [Table 1](#table1-1352458514536252){ref-type="table"}.

###### 

General characteristics of healthy subjects and patients with MS.

                              HC(*n* = 112)       All MS(*n* = 118)   CIS(*n* = 14)       RRMS(*n* = 34)      SPMS(*n* = 35)      PPMS(*n* = 35)
  --------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Age, years                  41.0 (28.0--52.0)   45.5 (38.0--54.0)   38.5 (27.3--42.3)   39.0 (32.3--47.3)   48.0 (40.0--55.0)   54.0 (46.0--56.0)
  Sex, % female               78.6                71.2                71.4                82.4                71.4                60.0
  Age of onset of MS, years                       34.5 (26.9--42.2)   37.3 (25.0--41.9)   32.0 (26.8--37.5)   29.0 (24.0--39.0)   40.0 (34.0--49.0)
  Duration of MS, years                           7.5 (2.8--17.0)     0.6 (0.1--1.3)      4.0 (1.6--11.5)     16.0 (10.0--24.0)   9.0 (5.0--17.0)
  EDSS score                                      5.0 (2.5--6.5)      1.0 (0.0--1.5)      2.3 (1.0--3.5)      6.5 (5.5--8.0)      6.5 (5.5--7.0)
  MSSS                                            6.6 (3.8--8.8)      2.4 (0.7--4.2)      4.4 (2.2--6.2)      7.8 (5.8--9.1)      8.5 (6.6--9.5)

All values except for sex presented as medians (interquartile ranges).

HC: healthy control subjects; All MS: total group of MS patients; CIS: clinically isolated syndrome; RRMS: relapsing--remitting MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; EDSS: Expanded Disability Status Scale; MSSS: MS Severity Score.

Flow cytometry {#section9-1352458514536252}
--------------

Peripheral blood mononuclear cells (PBMCs) were separated by density centrifugation and cryopreserved. Prior to analysis on a Beckman Coulter Gallios flow cytometer with seven color acquisition, cryopreserved PBMC samples were thawed and cultured for 24 h before use to allow cells to rest and re-express cell surface molecules. Cells were stained with Aqua Live/Dead cell exclusion dye (Invitrogen) and the following fluorochrome-conjugated antibodies: anti-CD3-allophycocyanin (APC) (Becton Dickinson), anti-CD4-V450 (Becton Dickinson), anti-CD8-APC-A700 (Beckman Coulter), anti-CD45RA-phycoerythrin-Cy7 (Becton Dickinson), anti-CD62L-APC-Cy7 (BioLegend) and anti-CCR7-peridinin chlorophyll protein-Cy5.5 (Becton Dickinson). Single labeled tubes for each antibody, isotype-matched control antibodies, fluorescence-minus-one controls, dead cell exclusion and doublet discrimination were used to ensure accurate positive cut-off values and compensation matrices and to validate cell phenotype detection sensitivity and resolution. [Figure 1](#fig1-1352458514536252){ref-type="fig"} shows the gating strategy used to identify the memory T cell subsets. Flow cytometry data was analyzed using Kaluza 1.2 software (Beckman Coulter).

![Flow cytometric gating strategy. Within the PBMCs of a healthy subject, lymphocytes (a) were identified on the basis of forward scatter and side scatter. We then identified the viable population of lymphocytes (b). The CD3^+^ T cell component of the viable cells (c) was then divided into CD4^+^ T cells and CD8^+^ T cells (d). Finally the CD4^+^ T cells and CD8^+^ T cells were subdivided into naïve, central memory (CM), effector memory (EM) and effector memory re-expressing CD45RA (EMRA) subsets according to the expression of CD45RA and CD62L ((e) and (f), respectively).](10.1177_1352458514536252-fig1){#fig1-1352458514536252}

Data analysis and statistics {#section10-1352458514536252}
----------------------------

Statistical analyses were performed using GraphPad Prism version 6.00 (Graphpad Software Inc., San Diego, CA, USA) and Sigmaplot 12.5 (Systat Software Inc., San Jose, CA, USA). Because most of the data was not normally distributed, the results have been presented as medians with interquartile ranges. For single comparisons between the whole group of MS patients and healthy subjects, Student's *t* test or the Mann--Whitney rank sum test was used, according to the distribution of the data. For comparisons between each of the subtypes of MS (CIS, CIS + RRMS, SPMS, PPMS, and All MS) and healthy subjects, we used Kruskal--Wallis non-parametric analysis of variance corrected for multiple comparisons (Dunn's Test). To assess the relationships between T cell frequencies and age, disease duration, Expanded Disability Status Scale (EDSS) score and MS Severity Score (MSSS) we used Spearman rank correlation. Differences were considered significant for *p* \<0.05.

Results {#section11-1352458514536252}
=======

The proportion of CD8^+^ T cells in the PBMC was decreased and the CD4:CD8 ratio was increased in MS patients compared with healthy subjects ([Table 2](#table2-1352458514536252){ref-type="table"}). Analysis of T cell memory phenotype based on CD45RA and CD62L expression revealed that the decreased frequency of total CD8^+^ T cells was due to a decrease in EM and EMRA T cells, which was present in all subtypes of MS (CIS + RRMS; SPMS; and PPMS) and at the onset of disease (CIS) ([Table 3](#table3-1352458514536252){ref-type="table"}). This was particularly evident when the frequencies of CD8^+^ EM and EMRA T cells were combined. In CIS/RRMS patients the T cell subset frequencies during attacks were not significantly different from those during remission. The absolute number of CD8^+^ EM/EMRA T cells was also decreased in the MS patients for whom this data was available (not shown). In contrast the frequencies of CD4^+^ EM and EMRA T cells were normal. The proportion of CD8^+^ CM T cells in the blood was higher in patients with MS than in healthy subjects, although the difference was not statistically significant after correction for multiple comparisons. In PPMS there was also a decrease in naïve CD8^+^ T cells ([Table 3](#table3-1352458514536252){ref-type="table"}). Reduced frequencies of CD8^+^ EM and EMRA T cells were also evident in MS patients when CCR7 was used instead of CD62L to analyze memory phenotype although the differences were not as significant as with CD62L (not shown). The frequencies of CD8^+^ EM, EMRA and EM/EMRA T cells within PBMCs were significantly lower in MS patients at all ages compared with healthy subjects ([Figure 2](#fig2-1352458514536252){ref-type="fig"}) but were not significantly correlated with disease duration, disability (EDSS) or severity (MSSS) (not shown).

###### 

Peripheral blood T cell frequencies.

                       \% CD3^+^                                                      \% CD4^+^CD3^+^                                                \% CD8^+^CD3^+^                                                  CD4:CD8 ratio
  -------------------- -------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  HC (*n* = 112)       69.11 (63.32--73.66)                                           44.48 (38.48--50.29)                                           18.61 (15.65--23.00)                                             2.27 (1.76--3.07)
  All MS (*n* = 118)   66.68 (59.18--72.88)                                           46.07 (39.47--52.07)                                           15.74 (12.62--20.43)                                             2.97 (2.16--3.77)
  *p* value            0.045^[a](#table-fn4-1352458514536252){ref-type="table-fn"}^   0.189^[b](#table-fn5-1352458514536252){ref-type="table-fn"}^   \<0.001^[b](#table-fn5-1352458514536252){ref-type="table-fn"}^   \<0.001^[a](#table-fn4-1352458514536252){ref-type="table-fn"}^

Values are presented as median (interquartile range) percentages of T cells within PBMCs.

Mann--Whitney rank sum test.

Student's *t* test.

HC: healthy control subjects; All MS: total group of MS patients.

###### 

Frequencies of memory T cell subsets.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          CD4^+^          CD8^+^                                                                                                       
  ----------------------- --------------- --------------- ---------------- --------------- -------------- -------------- -------------- -------------- ----------------
  HC (*n* = 112)          8.21            6.26            15.54            8.09            3.01           1.12           6.08           7.17           13.89

                          (5.63--14.12)   (3.95--11.09)   (12.72--19.76)   (4.90--12.06)   (1.90--4.79)   (0.64--1.81)   (4.29--7.84)   (5.18--9.99)   (10.91--17.09)

  All MS (*n* = 118)      8.40            6.80            18.02            8.79            2.71           1.42           4.87           5.25           10.57

                          (5.12--12.69)   (4.21--10.06)   (13.70--22.96)   (5.81--13.78)   (1.51--4.56)   (0.81--2.30)   (3.31--6.54)   (3.61--7.68)   (8.01--14.05)

  *p* value               \>0.999         \>0.999         0.119            \>0.999         \>0.999        0.110          **0.001**      **\<0.0001**   **\<0.0001**

  CIS + RRMS (*n* = 48)   8.04            6.94            17.29            8.79            3.97           1.34           4.61           5.95           11.12

                          (4.40--15.41)   (4.05--9.48)    (10.44--20.84)   (5.70--12.17)   (2.16--6.19)   (0.94--2.18)   (2.98--6.43)   (3.90--8.11)   (8.34--13.95)

  *p* value               \>0.999         \>0.999         \>0.999          \>0.999         0.880          0.364          **0.006**      0.082          **0.010**

  SPMS (*n* = 35)\        8.67            4.79            18.10            8.92            2.73           1.43           4.66           5.80           9.86

                          (5.44--11.99)   (3.89--10.03)   (15.18--22.94)   (6.08--14.57)   (1.83--4.04)   (0.80--2.41)   (3.39--6.09)   (4.15--8.38)   (8.73--14.39)

  *p* value               \>0.999         \>0.999         0.241            \>0.999         \>0.999        0.385          **0.022**      0.087          **0.005**

  PPMS (*n* = 35)         8.42            8.10            19.25            8.00            1.84           1.43           5.35           3.98           10.26

                          (5.09--12.33)   (5.62--10.82)   (13.73--24.70)   (5.62--14.39)   (0.99--3.05)   (0.60--2.49)   (3.27--6.97)   (2.73--6.72)   (7.28--13.40)

  *p* value               \>0.999         \>0.999         0.112            \>0.999         **0.009**      0.971          0.488          **\<0.0001**   **0.001**

  CIS (*n* = 14)          8.04            7.97            18.47            8.47            5.59           1.75           3.48           5.86           10.24

                          (6.01--16.05)   (5.15--10.38)   (10.19--21.29)   (6.34--15.60)   (2.53--9.59)   (1.06--2.62)   (2.81--5.16)   (4.75--8.57)   (8.26--12.23)

  *p* value               \>0.999         \>0.999         \>0.999          \>0.999         0.194          0.202          **0.004**      \>0.999        **0.044**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as median (interquartile range) percentages of memory T cell subsets within PBMCs. All *p* values are for comparisons with healthy control subjects (HC) using Kruskal--Wallis non-parametric analysis of variance corrected for multiple comparisons (Dunn's Test). Significant *p* values are highlighted in bold.

N: naïve T cells; CM: central memory; EM: effector memory; EMRA: effector memory re-expressing CD45RA; HC: healthy control subjects; All MS: total group of MS patients; RRMS: relapsing--remitting MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; CIS: clinically isolated syndrome

![Percentages of CD8^+^ EM (a), EMRA (b) and EM/EMRA (c) T cells in PBMCs in healthy subjects (HC) and the total group of MS patients (MS) plotted against age in years. On multiple linear regression analysis, the slopes of the regression lines are not significantly different but the y intercepts (elevations) for the MS patients are significantly different from those for the healthy subjects (*p* = 0.0027; *p* = 0.0001; *p* \<0.0001, respectively).](10.1177_1352458514536252-fig2){#fig2-1352458514536252}

Discussion {#section12-1352458514536252}
==========

In this study we have shown that patients with MS have a deficiency of CD8^+^ EM and EMRA T cells in peripheral blood. This deficiency is present at the onset of MS and persists throughout the clinical course. The decrease in CD8^+^ EM and EMRA T cells in the blood accounts for the well described decrease in total CD8^+^ T cells and increase in CD4:CD8 ratio in MS.^[@bibr5-1352458514536252][@bibr6-1352458514536252][@bibr7-1352458514536252][@bibr8-1352458514536252][@bibr9-1352458514536252][@bibr10-1352458514536252][@bibr11-1352458514536252][@bibr12-1352458514536252]--[@bibr13-1352458514536252]^ Previous studies on T cell memory subsets in MS have measured the frequencies of the subsets only within the total CD4^+^ and CD8^+^ T cell populations and not within the peripheral blood.^[@bibr18-1352458514536252][@bibr19-1352458514536252]--[@bibr20-1352458514536252]^ Therefore the conflicting findings of increased EM^[@bibr18-1352458514536252],[@bibr20-1352458514536252]^ and increased CM, normal EM and decreased EMRA^[@bibr19-1352458514536252]^ within the CD8^+^ population would not necessarily have applied to the actual frequencies of these subsets within the PBMC in the setting of a decreased total number of CD8^+^ T cells. This is illustrated in our study where the proportion of EM T cells within the CD8^+^ population in the total group of MS patients (32.5%) was the same as in the healthy control group (33.3%) despite the presence of a highly significant reduction in the frequency of CD8^+^ EM T cells in the PBMCs in the MS group (*p* = 0.001; [Table 3](#table3-1352458514536252){ref-type="table"}). In contrast to the reduction in CD8^+^ EM and EMRA T cells, the frequencies of CD4^+^ EM and EMRA T cells in the PBMC were not decreased in MS patients.

A major question is whether the reduction in CD8^+^ EM and EMRA T cells in MS is due to a primary deficiency of these cells or is secondary to the disease process. The increased CD4:CD8 ratio and reduced total CD8^+^ T cells in the blood have been attributed to sequestration of CD8^+^ T cells in the CNS^[@bibr11-1352458514536252]^ because CD8^+^ cells predominate over CD4^+^ cells in the T cell infiltrate within the CNS parenchyma.^[@bibr21-1352458514536252]^ However, the predominance of CD8^+^ over CD4^+^ T cells does not apply to other compartments of the CNS in MS, with equal numbers of CD4^+^ and CD8^+^ cells occurring in the perivascular infiltrates^[@bibr21-1352458514536252],[@bibr22-1352458514536252]^ and with CD4^+^ predominating over CD8^+^ T cells in the cerebrospinal fluid.^[@bibr23-1352458514536252]^ Therefore if lymphocyte sequestration in the inflamed CNS were to be incriminated as the cause of the reduction in circulating CD8^+^ T cells it would also be expected to cause a reduction in circulating CD4^+^ T cells, which is not the case. Indeed the frequency of CD4^+^ EM T cells in the blood was actually higher in MS patients than in healthy controls, although this difference was not statistically significant after allowing for multiple comparisons. Furthermore, even if CD8^+^ T cells were to predominate over CD4^+^ T cells within the sum total of CNS lymphocytes this would not necessarily increase the CD4:CD8 T cell ratio in the blood because a predominance of CD8^+^ over CD4^+^ T cells within the liver in chronic hepatitis C is not accompanied by an increased CD4:CD8 T cell ratio in the blood.^[@bibr24-1352458514536252]^ For the following reasons we propose that the deficiency of CD8^+^ EM and EMRA T cells is the result of a primary defect rather than being secondary to the MS disease process. First, the deficiency is present at the onset of MS and at all stages of the clinical course, including the relapsing--remitting and progressive phases. Second, it persists unchanged throughout the disease course and is not related to disability or disease severity; in particular, contrary to what would be expected if it were secondary to the disease process, it does not worsen with increasing severity or duration of MS. Third, CD8^+^ T cell deficiency and an increased CD4/CD8 ratio are features of many human chronic autoimmune diseases and are also present in the healthy blood relatives of patients with these diseases,^[@bibr25-1352458514536252]^ indicating that the abnormalities are genetically determined and not secondary to the disease process. In view of the cross-sectional nature of our study we do not know whether the T cell subset frequencies fluctuate over time in individual patients, particularly during concurrent infections or clinical attacks of MS. Longitudinal studies will be needed to answer this. Possible mechanisms causing deficiency of CD8^+^ EM and EMRA T cells include: (i) decreased proliferation and differentiation in response to antigen or homeostatic cytokines; and (ii) reduced cellular lifespan due to increased apoptosis. Our finding of an increased number of CD8^+^CD45RA^--^CD62L^+^ CM T cells in MS suggests impaired generation of EM and EMRA T cells from CD8^+^ CM, which normally acquire an EM phenotype after activation by antigen and an EM or EMRA phenotype in response to homeostatic cytokines.^[@bibr26-1352458514536252]^

In our study, patients with a primary progressive course of MS had a reduced frequency of naïve CD8^+^ T cells as well as a reduction in EM and EMRA cells. Moreover, the rate of decline in naïve CD8^+^ T cells with age in these patients was greater than the normal age-related decline in healthy controls (not shown). In healthy subjects this decline is due to thymic involution.^[@bibr27-1352458514536252]^ Our findings are consistent with a previous report of reduced thymic output of CD8^+^ T cells in PPMS.^[@bibr28-1352458514536252]^ In contrast, naïve CD4^+^ T cells were not decreased in PPMS in either our study or the previous report despite a reduction in the thymic output of naïve CD4^+^ T cells.^[@bibr28-1352458514536252]^ By reducing the number of naïve CD8^+^ T cells available to generate effector T cells in response to stimulation by antigen, the accelerated age-related decline in naïve CD8^+^ T cells is likely to contribute to the reduction of CD8^+^ EM and EMRA T cells in PPMS, especially in older patients. Accelerated age-related decline of naïve CD8^+^ T cells in PPMS accounts for our previous finding that the total CD8^+^ T cell population in the blood declines more rapidly in PPMS than in healthy subjects^[@bibr29-1352458514536252]^ and might explain why the onset of PPMS occurs on average 10 years later than that of RRMS.

In conclusion, we have shown that patients with MS have a deficiency of CD8^+^ EM and EMRA T cells in peripheral blood. This deficiency could underlie the defective CD8^+^ T cell control of EBV-infected B cells in MS.^[@bibr8-1352458514536252],[@bibr30-1352458514536252],[@bibr31-1352458514536252]^
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